Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes.
暂无分享,去创建一个
Rafael Freitas | B. Andrade | M. Barral-Netto | L. Correia | J. Esteves | Bruno B Andrade | Manoel Barral-Netto | Luis C L Correia | Valéria M Borges | Jorge Clarêncio | Ana P Bittencourt | Alexandre C Souza | Maria C Almeida | Jamile Leal | J Péricles Esteves | J. Clarêncio | V. M. Borges | M. C. Almeida | Rafael Freitas | A. P. Bittencourt | A. C. Souza | J. Leal | J. Clarêncio
[1] A. Yan,et al. Understanding physicians' risk stratification of acute coronary syndromes: insights from the Canadian ACS 2 Registry. , 2009, Archives of internal medicine.
[2] N Rifai,et al. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. , 1999, Clinical chemistry.
[3] I. Penttilä,et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-α in the prognostic classification of unstable angina pectoris , 2001 .
[4] T. Kılıç,et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome , 2006, Heart.
[5] Nikolaos Laoutaris,et al. Prognostic Value of C‐Reactive Protein, Fibrinogen, Interleukin‐6, and Macrophage Colony Stimulating Factor in Severe Unstable Angina , 2002, Clinical cardiology.
[6] Pedro de Araújo Gonçalves,et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. , 2005 .
[7] D. Morrow,et al. The future of biomarkers in the management of patients with acute coronary syndromes , 2008, Current opinion in cardiology.
[8] P. Libby,et al. Inflammation and Atherosclerosis , 2002, Circulation.
[9] M. Halinen,et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. , 2001, Annals of medicine.
[10] M. Sabatine,et al. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. , 2006, Circulation.
[11] Sidney C. Smith,et al. MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .
[12] L. Correia,et al. Does high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-ST elevation acute coronary syndromes? , 2007, Clinica chimica acta; international journal of clinical chemistry.
[13] R. Califf,et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. , 2007, Journal of the American College of Cardiology.
[14] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[15] Carlos Aguiar,et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. , 2005, European heart journal.
[16] P. Kovanen,et al. Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. , 2004, The American journal of cardiology.
[17] Chen,et al. Simultaneous Quantification of Six Human Cytokines in a Single Sample Using Microparticle-based Flow Cytometric Technology. , 1999, Clinical chemistry.
[18] A. Jaffe,et al. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. , 2007, Clinical chemistry.
[19] E. Antman,et al. Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.
[20] J. Herlitz,et al. C‐reactive protein, interleukin‐6, secretory phospholipase A2 group IIA and intercellular adhesion molecule‐1 in the prediction of late outcome events after acute coronary syndromes , 2007, Journal of internal medicine.
[21] A. Yan,et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. , 2007, European heart journal.
[22] P. Delves,et al. The immune system. Second of two parts. , 2000, The New England journal of medicine.
[23] J. Kaski,et al. Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. , 2007, Atherosclerosis.
[24] C. Heeschen,et al. Serum Level of the Antiinflammatory Cytokine Interleukin-10 Is an Important Prognostic Determinant in Patients With Acute Coronary Syndromes , 2003, Circulation.
[25] P. Doyle,et al. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. , 2003, Clinical chemistry.
[26] M. Brockhaus,et al. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. , 1992, The Journal of clinical investigation.
[27] A. Hamsten,et al. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome , 2007, Heart.
[28] P. Järemo,et al. Interleukin-6 and neutrophils are associated with long-term survival after acute myocardial infarction. , 2008, European journal of internal medicine.
[29] G. Sanz,et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. , 2002, American heart journal.
[30] H. Putter,et al. CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms , 2007, Circulation.
[31] Á. Avezum,et al. Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.
[32] G. Lip,et al. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. , 2005, Blood.
[33] H. Putter,et al. CCL3 (MIP-1 alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. , 2008, Journal of molecular and cellular cardiology.
[34] T. Ueland,et al. Chemokines and Cardiovascular Risk , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[35] J. Kaski,et al. Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. , 2007, International journal of cardiology.
[36] A. Rebuzzi,et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.
[37] P. Delves,et al. The Immune System , 2000 .